Atara Biotherapeutics, Inc. (ATRA)’s Stock Insider Trade – Christopher Haqq Sold 18,327 Shares; Q Global Advisors Has Lowered By $1.44 Million Its Costamare (CMRE) Position

Q Global Advisors Llc decreased Costamare Inc (CMRE) stake by 29.19% reported in 2017Q4 SEC filing. Q Global Advisors Llc sold 288,608 shares as Costamare Inc (CMRE)’s stock rose 5.46%. The Q Global Advisors Llc holds 700,000 shares with $4.04 million value, down from 988,608 last quarter. Costamare Inc now has $674.83M valuation. The stock decreased 0.48% or $0.03 during the last trading session, reaching $6.18. About 450,111 shares traded. Costamare Inc. (NYSE:CMRE) has declined 0.48% since March 28, 2017 and is downtrending. It has underperformed by 12.03% the S&P500.

After the disclosing of a public form filled with D.C. based-SEC; a sale became apparent. The EVP – R&D & Chief Scientific Of of Atara Biotherapeutics Inc, Christopher Haqq; finalized a transaction in the open market by unloading 18,327 shares at the avg market share price which was $39.8 of the Pinksheet-listed company having a market value near $729,265 US Dollars. Presently, he has 352,905 shares or 0.82% of Atara Biotherapeutics Inc’s market cap.

Since October 11, 2017, it had 0 insider purchases, and 18 insider sales for $8.63 million activity. $900,815 worth of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) was sold by MCGRATH JOHN on Thursday, January 11. Gallagher Carol Giltner also sold $55,010 worth of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) on Thursday, February 15. Ciechanover Isaac E. sold $18,228 worth of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) on Tuesday, January 16. Another trade for 6,000 shares valued at $86,100 was sold by Haqq Christopher. Another trade for 12,214 shares valued at $464,210 was sold by Turner Heather D.

Atara Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for patients with severe and life-threatening diseases in the United States. The company has market cap of $1.66 billion. The Company’s clinical stage T-cell product candidates include ATA129 that focuses on Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus associated post-transplant lymphoproliferative disorder after hematopoietic cell transplant and solid organ transplant; ATA188, which is in Phase I clinical trial for the treatment of multiple sclerosis; ATA520, a Phase I clinical trial product targeting cancers expressing the antigen Wilms tumor 1; and ATA230, which is Phase III clinical trials for refractory cytomegalovirus. It currently has negative earnings. The firm is also developing a next generation of allogeneic T-cell product candidates utilizing a technology to selectively enhance a T-cellÂ’s ability to target specific viral proteins implicated in disease.

Investors sentiment decreased to 1.42 in Q4 2017. Its down 0.12, from 1.54 in 2017Q3. It is negative, as 9 investors sold Atara Biotherapeutics, Inc. shares while 17 reduced holdings. 12 funds opened positions while 25 raised stakes. 27.87 million shares or 6.54% more from 26.16 million shares in 2017Q3 were reported. Moreover, Schwab Charles Inv Mngmt Incorporated has 0% invested in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) for 104,612 shares. Her Majesty The Queen In Right Of The Province Of Alberta As Represented By Alberta Mngmt Corporation, a Alberta – Canada-based fund reported 39,330 shares. Redmile Group Inc Ltd Com accumulated 2.22% or 2.82M shares. Morgan Stanley stated it has 1.74M shares or 0.01% of all its holdings. Hudson Bay Cap Mngmt L P invested in 0.01% or 25,000 shares. Bridger Management Ltd Limited Liability Company, New York-based fund reported 2.60 million shares. Vanguard Group has invested 0% in Atara Biotherapeutics, Inc. (NASDAQ:ATRA). 535,500 are held by Camber Capital Lc. Manufacturers Life Insur Co The invested 0% in Atara Biotherapeutics, Inc. (NASDAQ:ATRA). Moreover, 12 West Capital Mgmt Limited Partnership has 0.87% invested in Atara Biotherapeutics, Inc. (NASDAQ:ATRA). Comml Bank Of America De owns 0% invested in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) for 100,768 shares. 3,948 were reported by Parallax Volatility Advisers Limited Partnership. Tiaa Cref Invest Management Ltd invested in 61,978 shares or 0% of the stock. Swiss Fincl Bank has invested 0% of its portfolio in Atara Biotherapeutics, Inc. (NASDAQ:ATRA). Northern Tru, a Illinois-based fund reported 288,773 shares.

The stock decreased 6.44% or $2.65 during the last trading session, reaching $38.5. About 1.29 million shares traded or 11.77% up from the average. Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has risen 88.73% since March 28, 2017 and is uptrending. It has outperformed by 77.18% the S&P500.

Analysts await Atara Biotherapeutics, Inc. (NASDAQ:ATRA) to report earnings on May, 3. They expect $-0.92 EPS, down 4.55% or $0.04 from last year’s $-0.88 per share. After $-1.15 actual EPS reported by Atara Biotherapeutics, Inc. for the previous quarter, Wall Street now forecasts -20.00% EPS growth.

Among 8 analysts covering Atara Biotherapeutics (NASDAQ:ATRA), 4 have Buy rating, 1 Sell and 3 Hold. Therefore 50% are positive. Atara Biotherapeutics has $80 highest and $8 lowest target. $35.40’s average target is -8.05% below currents $38.5 stock price. Atara Biotherapeutics had 24 analyst reports since September 9, 2015 according to SRatingsIntel. The stock of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has “Market Perform” rating given on Wednesday, February 28 by JMP Securities. On Thursday, August 31 the stock rating was maintained by Jefferies with “Buy”. The firm has “Buy” rating given on Monday, October 24 by Jefferies. The stock has “Market Outperform” rating by JMP Securities on Wednesday, March 9. The stock has “Sell” rating by Citigroup on Monday, August 22. The company was initiated on Friday, September 25 by JMP Securities. Jefferies maintained it with “Buy” rating and $46.0 target in Monday, March 5 report. The rating was initiated by Goldman Sachs on Wednesday, November 18 with “Neutral”. As per Tuesday, December 15, the company rating was maintained by JMP Securities. The stock of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has “Sell” rating given on Friday, August 19 by Citigroup.